Sorafenib targets the Raf/mitogen-activated protein kinase, VEGF, and platelet-derived
growth factor pathways and prolongs survival patients in advanced hepatocellular …

Purpose: Few treatment options are available for patients with advanced or metastatic
hepatocellular carcinoma (HCC). Based on preclinical and early clinical efficacy signals and …

Trial registry Clinicaltrials. gov# NCT01180959. Background Early clinical studies of
bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) have a tolerable …

240 Background: The combination of the imidazotetrazine derivative temozolomide (TMZ)
and poly (ADP-ribose) polymerase inhibitor veliparib (ABT-888) has shown in vivo activity …

Background The efficacy of bevacizumab combined with erlotinib (B+ E) for the treatment of
advanced hepatocellular carcinoma, especially for sorafenib-refractory patients, has been …

A multicenter randomized controlled trial established sorafenib as a standard of care for
patients with advanced hepatocellular carcinoma (HCC). Because the study was …

Background and aims: Prospective randomized trials have proven that sorafenib is a valid
treatment option for patients with advanced-stage hepatocellular carcinoma (HCC). The aim …

Background Deregulation of mammalian target of rapamycin (mTOR) signalling is common
in human hepatocellular carcinoma (HCC). Aim To determine the maximum tolerated dose …

4103 Background: Sorafenib (S) is the only approved systemic treatment for unresectable
HCC. Nevertheless, there remains an unmet medical need for more effective treatment …

Results A total of 60 patients received sorafenib and transarterial therapy. There was no CR;
2 (3.3%) patients achieved partial response, but 30 patients (50.0%) achieved stable …